In AF or VTE, acenocoumarol or phenprocoumon dosing by genotype did not affect time in therapeutic range

被引：0
|
作者：
Dunn, Andrew [1 ]
机构：
[1] Mt Sinai Hlth Syst, New York, NY 10029 USA
来源：
ANNALS OF INTERNAL MEDICINE | 2014年 / 160卷 / 06期
关键词：
D O I：
10.7326/0003-4819-160-6-201403180-02010
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 39 条
  • [1] In AF or VTE, warfarin dosing by genotype improved time in therapeutic range but not clinical outcomes
    Pirmohamed, M.
    Burnside, G.
    Eriksson, N.
    ANNALS OF INTERNAL MEDICINE, 2014, 160 (06)
  • [2] Warfarin dosing by genotype did not improve time in therapeutic range
    Dunn, Andrew
    ANNALS OF INTERNAL MEDICINE, 2014, 160 (06)
  • [3] A Randomized Trial of Genotype-Guided Dosing of Acenocoumarol and Phenprocoumon
    Verhoef, Talitha I.
    Ragia, Georgia
    de Boer, Anthonius
    Barallon, Rita
    Kolovou, Genovefa
    Kolovou, Vana
    Konstantinides, Stavros
    Le Cessie, Saskia
    Maltezos, Efstratios
    van der Meer, Felix J. M.
    Redekop, William K.
    Remkes, Mary
    Rosendaal, Frits R.
    van Schie, Rianne M. F.
    Tavridou, Anna
    Tziakas, Dimitrios
    Wadelius, Mia
    Manolopoulos, Vangelis G.
    Maitland-van der Zee, Anke H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (24): : 2304 - 2312
  • [4] Age-Stratified Outcome Of Genotype-Guided Dosing Algorithm For Acenocoumarol And Phenprocoumon
    Zhang, Yumao
    De Boer, Anthonius
    Verhoef, Talitha I.
    Van der Meer, Felix J. M.
    Le Cessie, Saskia
    Manolopoulos, Vangelis G.
    Maitland-Van der Zee, Anke H.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 570 - 571
  • [5] Age-stratified outcome of a genotype-guided dosing algorithm for acenocoumarol and phenprocoumon
    Zhang, Y.
    de Boer, A.
    Verhoef, T. I.
    van der Meer, F. J. M.
    Le Cessie, S.
    Manolopoulos, V. G.
    Maitland-van der Zee, A. H.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2017, 15 (03) : 454 - 464
  • [6] Effect of switching from acenocoumarol to phenprocoumon on time in therapeutic range and INR variability: A cohort study
    van Miert, Jasper H. A.
    Veeger, Nic J. G. M.
    ten Cate-Hoek, Arina J.
    Piersma-Wichers, Margriet
    Meijer, Karina
    PLOS ONE, 2020, 15 (07):
  • [7] ANTICOAGULATION IN AF: IS TIME IN THERAPEUTIC RANGE NICE?
    Merinopoulos, Ioannis
    Venables, Paul
    Chalmers, Isobel
    Vassiliou, Vassilis
    HEART, 2015, 101 : A33 - A33
  • [8] Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol
    Miguel Rivera-Caravaca, Jose
    Roldar, Vanessa
    Asuncion Esteve-Pastor, Maria
    Valdes, Mariano
    Vicente, Vicente
    Marin, Francisco
    Lip, Gregory Y. H.
    CLINICAL THERAPEUTICS, 2018, 40 (01) : 114 - 122
  • [9] Genotype-Guided Vitamin K Antagonist Dosing Algorithms Improve Time in Therapeutic Range: A Systematic Review and Meta-Analysis
    BeIley-Cote, Emilie P.
    Hanif, Hasib
    D'Aragon, Frederick
    Eikelboom, John
    Anderson, Jeffrey L.
    Borgman, Mark
    Jonas, Daniel E.
    Kimmel, Stephen
    Maitland-van der Zee, Anke H.
    Pirmohamed, Munir
    Whitlock, Richard
    CIRCULATION, 2014, 130
  • [10] Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects
    D B Hawcutt
    A A Ghani
    L Sutton
    A Jorgensen
    E Zhang
    M Murray
    H Michael
    I Peart
    R L Smyth
    M Pirmohamed
    The Pharmacogenomics Journal, 2014, 14 : 542 - 548
1234